• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 11-K filed by Becton Dickinson and Company

    6/29/26 4:18:28 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care
    Get the next $BDX alert in real time by email
    bdx-20260629
    FalseFalse000001079500000107950.33iso4217:USDxbrli:pureutr:Hbdx:yearxbrli:shares00000107952025-01-012025-12-310000010795bdx:EBP011Member2025-01-012025-12-310000010795bdx:EBP011Member2025-12-310000010795bdx:EBP011Member2024-12-310000010795bdx:EBP011Membersrt:MinimumMember2025-01-012025-12-310000010795bdx:EBP011Membersrt:MaximumMember2025-01-012025-12-310000010795bdx:EBP011Membersrt:ScenarioForecastMember2027-01-012027-12-310000010795bdx:EBP011Memberbdx:EBPVestingTermOneMember2025-01-012025-12-310000010795bdx:EBP011Memberbdx:EBPVestingTermTwoMember2025-01-012025-12-310000010795bdx:EBP011Memberbdx:EBPVestingTermThreeMember2025-01-012025-12-310000010795bdx:EBP011Memberbdx:EBPVestingTermFourMember2025-01-012025-12-310000010795us-gaap-ebp:EmployeeBenefitPlanUnallocatedMemberbdx:EBP011Member2025-12-310000010795us-gaap-ebp:EmployeeBenefitPlanUnallocatedMemberbdx:EBP011Member2024-12-310000010795us-gaap-ebp:EmployeeBenefitPlanEmployerCommonStockMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberbdx:EBP011Member2025-12-310000010795us-gaap-ebp:EmployeeBenefitPlanEmployerCommonStockMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedPlanInterestInMasterTrustMemberbdx:EBP011Member2025-12-310000010795us-gaap:DefinedBenefitPlanCommonCollectiveTrustMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberbdx:EBP011Member2025-12-310000010795us-gaap:DefinedBenefitPlanCommonCollectiveTrustMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedPlanInterestInMasterTrustMemberbdx:EBP011Member2025-12-310000010795us-gaap:MutualFundMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberbdx:EBP011Member2025-12-310000010795us-gaap:MutualFundMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedPlanInterestInMasterTrustMemberbdx:EBP011Member2025-12-310000010795us-gaap:CashAndCashEquivalentsMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberbdx:EBP011Member2025-12-310000010795us-gaap:CashAndCashEquivalentsMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedPlanInterestInMasterTrustMemberbdx:EBP011Member2025-12-310000010795bdx:EBP011Memberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMember2025-12-310000010795bdx:EBP011Memberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedPlanInterestInMasterTrustMember2025-12-310000010795us-gaap-ebp:EmployeeBenefitPlanEmployerCommonStockMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberbdx:EBP011Member2024-12-310000010795us-gaap-ebp:EmployeeBenefitPlanEmployerCommonStockMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedPlanInterestInMasterTrustMemberbdx:EBP011Member2024-12-310000010795us-gaap:DefinedBenefitPlanCommonCollectiveTrustMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberbdx:EBP011Member2024-12-310000010795us-gaap:DefinedBenefitPlanCommonCollectiveTrustMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedPlanInterestInMasterTrustMemberbdx:EBP011Member2024-12-310000010795us-gaap:MutualFundMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberbdx:EBP011Member2024-12-310000010795us-gaap:MutualFundMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedPlanInterestInMasterTrustMemberbdx:EBP011Member2024-12-310000010795us-gaap:CashAndCashEquivalentsMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberbdx:EBP011Member2024-12-310000010795us-gaap:CashAndCashEquivalentsMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedPlanInterestInMasterTrustMemberbdx:EBP011Member2024-12-310000010795bdx:EBP011Memberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMember2024-12-310000010795bdx:EBP011Memberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedPlanInterestInMasterTrustMember2024-12-310000010795bdx:EBP011Memberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMember2025-01-012025-12-310000010795bdx:EBP011Memberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedPlanInterestInMasterTrustMember2025-01-012025-12-310000010795us-gaap:DefinedBenefitPlanCommonCollectiveTrustMemberbdx:EBP011Memberus-gaap:FairValueInputsLevel1Member2025-12-310000010795us-gaap:DefinedBenefitPlanCommonCollectiveTrustMemberbdx:EBP011Memberus-gaap:FairValueInputsLevel2Member2025-12-310000010795us-gaap:DefinedBenefitPlanCommonCollectiveTrustMemberbdx:EBP011Memberus-gaap:FairValueInputsLevel3Member2025-12-310000010795us-gaap:DefinedBenefitPlanCommonCollectiveTrustMemberbdx:EBP011Memberus-gaap:FairValueInputsLevel12And3Member2025-12-310000010795us-gaap:CashAndCashEquivalentsMemberbdx:EBP011Memberus-gaap:FairValueInputsLevel1Member2025-12-310000010795us-gaap:CashAndCashEquivalentsMemberbdx:EBP011Memberus-gaap:FairValueInputsLevel2Member2025-12-310000010795us-gaap:CashAndCashEquivalentsMemberbdx:EBP011Memberus-gaap:FairValueInputsLevel3Member2025-12-310000010795us-gaap:CashAndCashEquivalentsMemberbdx:EBP011Memberus-gaap:FairValueInputsLevel12And3Member2025-12-310000010795us-gaap:MutualFundMemberbdx:EBP011Memberus-gaap:FairValueInputsLevel1Member2025-12-310000010795us-gaap:MutualFundMemberbdx:EBP011Memberus-gaap:FairValueInputsLevel2Member2025-12-310000010795us-gaap:MutualFundMemberbdx:EBP011Memberus-gaap:FairValueInputsLevel3Member2025-12-310000010795us-gaap:MutualFundMemberbdx:EBP011Memberus-gaap:FairValueInputsLevel12And3Member2025-12-310000010795us-gaap-ebp:EmployeeBenefitPlanEmployerCommonStockMemberbdx:EBP011Memberus-gaap:FairValueInputsLevel1Member2025-12-310000010795us-gaap-ebp:EmployeeBenefitPlanEmployerCommonStockMemberbdx:EBP011Memberus-gaap:FairValueInputsLevel2Member2025-12-310000010795us-gaap-ebp:EmployeeBenefitPlanEmployerCommonStockMemberbdx:EBP011Memberus-gaap:FairValueInputsLevel3Member2025-12-310000010795us-gaap-ebp:EmployeeBenefitPlanEmployerCommonStockMemberbdx:EBP011Memberus-gaap:FairValueInputsLevel12And3Member2025-12-310000010795bdx:EBP011Memberus-gaap:FairValueInputsLevel1Member2025-12-310000010795bdx:EBP011Memberus-gaap:FairValueInputsLevel2Member2025-12-310000010795bdx:EBP011Memberus-gaap:FairValueInputsLevel3Member2025-12-310000010795bdx:EBP011Memberus-gaap:FairValueInputsLevel12And3Member2025-12-310000010795us-gaap:DefinedBenefitPlanCommonCollectiveTrustMemberbdx:EBP011Memberus-gaap:FairValueInputsLevel1Member2024-12-310000010795us-gaap:DefinedBenefitPlanCommonCollectiveTrustMemberbdx:EBP011Memberus-gaap:FairValueInputsLevel2Member2024-12-310000010795us-gaap:DefinedBenefitPlanCommonCollectiveTrustMemberbdx:EBP011Memberus-gaap:FairValueInputsLevel3Member2024-12-310000010795us-gaap:DefinedBenefitPlanCommonCollectiveTrustMemberbdx:EBP011Memberus-gaap:FairValueInputsLevel12And3Member2024-12-310000010795us-gaap:CashAndCashEquivalentsMemberbdx:EBP011Memberus-gaap:FairValueInputsLevel1Member2024-12-310000010795us-gaap:CashAndCashEquivalentsMemberbdx:EBP011Memberus-gaap:FairValueInputsLevel2Member2024-12-310000010795us-gaap:CashAndCashEquivalentsMemberbdx:EBP011Memberus-gaap:FairValueInputsLevel3Member2024-12-310000010795us-gaap:CashAndCashEquivalentsMemberbdx:EBP011Memberus-gaap:FairValueInputsLevel12And3Member2024-12-310000010795us-gaap:MutualFundMemberbdx:EBP011Memberus-gaap:FairValueInputsLevel1Member2024-12-310000010795us-gaap:MutualFundMemberbdx:EBP011Memberus-gaap:FairValueInputsLevel2Member2024-12-310000010795us-gaap:MutualFundMemberbdx:EBP011Memberus-gaap:FairValueInputsLevel3Member2024-12-310000010795us-gaap:MutualFundMemberbdx:EBP011Memberus-gaap:FairValueInputsLevel12And3Member2024-12-310000010795us-gaap-ebp:EmployeeBenefitPlanEmployerCommonStockMemberbdx:EBP011Memberus-gaap:FairValueInputsLevel1Member2024-12-310000010795us-gaap-ebp:EmployeeBenefitPlanEmployerCommonStockMemberbdx:EBP011Memberus-gaap:FairValueInputsLevel2Member2024-12-310000010795us-gaap-ebp:EmployeeBenefitPlanEmployerCommonStockMemberbdx:EBP011Memberus-gaap:FairValueInputsLevel3Member2024-12-310000010795us-gaap-ebp:EmployeeBenefitPlanEmployerCommonStockMemberbdx:EBP011Memberus-gaap:FairValueInputsLevel12And3Member2024-12-310000010795bdx:EBP011Memberus-gaap:FairValueInputsLevel1Member2024-12-310000010795bdx:EBP011Memberus-gaap:FairValueInputsLevel2Member2024-12-310000010795bdx:EBP011Memberus-gaap:FairValueInputsLevel3Member2024-12-310000010795bdx:EBP011Memberus-gaap:FairValueInputsLevel12And3Member2024-12-310000010795bdx:EBP011Memberus-gaap-ebp:EmployeeBenefitPlanEmployerCommonStockMember2025-12-310000010795bdx:EBP011Memberus-gaap-ebp:EmployeeBenefitPlanEmployerCommonStockMember2024-12-310000010795bdx:EBP011Memberus-gaap-ebp:EmployeeBenefitPlanEmployerCommonStockMember2025-01-012025-12-310000010795us-gaap:SubsequentEventMemberbdx:EBP011Member2026-02-09

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549


    FORM 11-K


    ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE

    SECURITIES AND EXCHANGE ACT OF 1934

    ☒ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

    For the fiscal year ended December 31, 2025

    OR

    ☐ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

    For the transition period from to

    Commission file number 1-4802



    BD 401(k) Plan

    (FULL TITLE OF THE PLAN)

    BECTON, DICKINSON AND COMPANY

    (NAME OF ISSUER OF SECURITIES HELD PURSUANT TO THE PLAN)



    1 Becton Drive07417-1880
    Franklin Lakes, New Jersey(Zip Code)
    (ADDRESS OF PRINCIPAL EXECUTIVE OFFICER)
    (201) 847-5604
    (Telephone Number)


    Table of Contents

    1.    FINANCIAL STATEMENTS AND SUPPLEMENTAL SCHEDULE.
    The following financial data for the Plan are submitted herewith:
    Report of Independent Registered Public Accounting Firm
    Statements of Net Assets Available for Benefits as of December 31, 2025 and 2024
    Statement of Changes in Net Assets for Benefits for the year ended December 31, 2025
    Notes to Financial Statements
    Schedule H, Line 4 (i) - Schedule of Assets (Held at End of Year)
    2.1    EXHIBITS.
    See Exhibit Index for a list of Exhibits filed or incorporated by reference as part of this report.



    ANNUAL REPORT ON FORM 11-K
    FINANCIAL STATEMENTS
    AND SUPPLEMENTAL SCHEDULE
    BD 401(k) Plan
    December 31, 2025 and 2024
    With Report of Independent Registered Public
    Accounting Firm



    Annual Report on Form 11-K
    BD 401(k) Plan
    Financial Statements and Supplemental Schedule
    December 31, 2025 and 2024 and for the Year Ended December 31, 2025
    Table of Contents

    Report of Independent Registered Public Accounting Firm
    1
    Financial Statements
    Statements of Net Assets Available for Benefits
    3
    Statement of Changes in Net Assets Available for Benefits
    4
    Notes to Financial Statements
    5
    Supplemental Schedule
    16
    Schedule H, Line 4(i) - Schedule of Assets (Held at End or Year)
    17
    Exhibit
    Consent
    19



    Report of Independent Registered Public Accounting Firm
    To the Plan Participants and the Plan Administrator of BD 401(k) Plan
    Opinion on the Financial Statements
    We have audited the accompanying statements of net assets available for benefits of BD 401(k) Plan (the Plan) as of December 31, 2025 and 2024, and the related statement of changes in net assets available for benefits for the year ended December 31, 2025, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the net assets available for benefits of the Plan at December 31, 2025 and 2024, and the changes in its net assets available for benefits for the year ended December 31, 2025, in conformity with U.S. generally accepted accounting principles.
    Basis for Opinion
    These financial statements are the responsibility of the Plan’s management. Our responsibility is to express an opinion on the Plan’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Plan in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
    We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Plan is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Plan’s internal control over financial reporting. Accordingly, we express no such opinion.
    Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
    Supplemental Schedule Required by ERISA
    The accompanying supplemental schedule of assets (held at end of year) as of December 31, 2025 (referred to as the “supplemental schedule”), has been subjected to audit procedures performed in conjunction with the audit of the Plan’s financial statements. The information in the supplemental schedule is the responsibility of the Plan’s management. Our audit procedures included determining whether the information reconciles to the financial statements or the underlying accounting and other records, as applicable, and performing procedures to test the completeness and accuracy of the information presented in the supplemental schedule. In forming our opinion on the information, we evaluated whether such information, including its form and content, is presented in conformity with the Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee
    1


    Retirement Income Security Act of 1974. In our opinion, the information is fairly stated, in all material respects, in relation to the financial statements as a whole.

    /s/ Ernst & Young LLP
    We have served as the Plan’s auditor since at least 1986, but we are unable to determine the specific year.

    New York, New York
    June 29, 2026
    2


    BD 401(k) Plan
    Statements of Net Assets Available for Benefits

    December 31,

    20252024
    Assets



      Beneficial interest in BD Defined Contribution Plan Master Trust
    $6,316,624,894 

    $5,702,389,182 
      Notes receivable from participants
    72,906,552 

    69,266,803 
      Contributions receivable – Company
    104,985,912 

    64,680,670 
      Pending trade settlements
    1,261,930 2,720,408 
      Total assets
    $6,495,779,288 

    $5,839,057,063 
    Liabilities

      Pending trade settlements
    $1,618,927 

    $2,718,896 
      Investment management fees payable
    821,623 1,233,278 
      Total liabilities
    2,440,550 3,952,174 
    Net assets available for benefits
    $6,493,338,738 

    $5,835,104,889 
    See accompanying notes.
    3


    BD 401(k) Plan
    Statement of Changes in Net Assets Available for Benefits
    Year Ended December 31, 2025

    Additions:

    Net appreciation, interest and dividends from beneficial interest in BD Defined Contribution Plan Master Trust
    $845,542,331 
    Interest income on notes receivable from participants
    5,723,918 
    Participants’ contributions
    249,568,982 
    Rollover contributions
    66,462,353 
    Company contributions
    206,876,547 
    Total Additions
    $1,374,174,131 
    Deductions:
    Benefits paid directly to participants and beneficiaries
    $714,817,349 
    Administrative expenses
    1,122,933 
    Total Deductions
    $715,940,282 
    Net increase in net assets available for benefits
    $658,233,849 
    Net assets available for benefits at beginning of year
    5,835,104,889 
    Net assets available for benefits at end of year
    $6,493,338,738 
    See accompanying notes.
    4


    BD 401(k) Plan
    Notes to Financial Statements
    December 31, 2025
    1. Significant Accounting Policies
    Basis of Accounting
    The accounting records of the BD 401(k) Plan (the Plan) are maintained on the accrual basis of accounting.
    Cash Equivalents
    The Plan considers all highly-liquid investments with a maturity of 90 days or less when purchased to be cash equivalents.
    Benefit Payments
    Benefit payments are recorded when paid.
    Administrative Expenses
    Investment management fees, brokerage fees, commissions, stock transfer taxes, and other expenses related to each investment fund are paid out of the respective fund. Other expenses, such as trustee fees, and other administrative expenses are shared by Becton, Dickinson and Company (BD or the Company) and the Plan. Expenses that are paid by the Company are excluded from these financial statements.
    Notes Receivable from Participants
    Notes receivable from participants represent participant loans that are recorded at their unpaid principal balance plus any accrued but unpaid interest. Interest income on notes receivable from participants is recorded when it is earned. Related fees are recorded as administrative expenses and are expensed when they are incurred. No allowance for credit losses has been recorded as of December 31, 2025 or December 31, 2024. If a participant ceases to make loan repayments and the plan administrator deems the participant loan to be a distribution, the participant loan is reduced and a benefit payment is recorded. At December 31, 2025, the interest rates on notes receivable from participants ranged from 3.25% to 9.50% with maturities ranging from 2026 to 2047.
    Use of Estimates
    The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes and supplemental schedule. Actual results could differ from those estimates.
                5


    Investment Valuation and Income Recognition
    Investments are stated at fair value with the exception of the stable value fund noted below. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). See Note 4 for further discussion and disclosures related to fair value measurements.
    Participants have the option of investing in a stable value fund which is a separately managed account. The stable value fund purchases synthetic investment contracts (Synthetic GICs). These investment contracts are recorded at contract value (see Note 5). Contract value is the relevant measurement attributable to fully benefit-responsive investment contracts because contract value is the amount participants would receive if they were to initiate permitted transactions under the terms of the Plan. The contract value of the fully benefit-responsive investment contracts represents contributions plus earnings, less participant withdrawals and administrative expenses.
    Purchases and sales of securities are recorded on a trade-date basis. Interest income is recorded as earned. Dividends are recorded on the ex-dividend date. Net appreciation includes the Plan’s gains and losses on investments bought and sold as well as held during the year (see Note 3 for description of how income from the BD Defined Contribution Plan Master Trust (the Master Trust) is attributed to the Plan).
    2. Description of the Plan
    The following description of the Plan only includes general information. Please refer to the Plan document for a more complete description of the Plan’s provisions.
    General
    The Plan is a defined contribution plan established for the purpose of encouraging and assisting employees in following a systematic savings program in various types of investments, including stock of the Company. Full-time and part-time employees of the Company and certain of its domestic subsidiaries are eligible for participation in the Plan on the first enrollment date coincident with or next following their date of hire. Temporary employees are eligible for participation in the Plan after the completion of 1,000 hours of service as defined by the Plan. Becton, Dickinson and Company is the sponsor of the Plan.
    The Plan is subject to certain provisions of the Employee Retirement Income Security Act of 1974, as amended (ERISA). The Plan is designed to meet ERISA’s reporting and disclosure and fiduciary responsibility requirements, as well as the minimum standards for participation and vesting. The Plan is not, however, subject to ERISA’s minimum funding standards, nor are benefits under the Plan eligible for the termination insurance provided by the Pension Benefit Guaranty Corporation.
    Master Trust
    As of December 31, 2025 and 2024, the Plan, as well as the BD Savings Plan for Puerto Rico Employees participated in the Master Trust.
    6



    The Administrative Committee consists of certain employees of the Company and administers the Plan. Fidelity Management Trust Company is the trustee of the Master Trust (the Trustee) and Fidelity Workplace Services, LLC is the Plan’s record-keeper.
    Contributions
    Eligible employees who are members of the Plan can authorize a payroll deduction for a contribution to the Plan in an amount per payroll period equal to any selected whole percentage of eligible compensation from 1% to 60%. Employees who do not make an election not to participate are automatically enrolled at a deferral rate of 6% of eligible compensation. For purposes of the Plan, eligible compensation includes base pay, overtime compensation, commissions and regular bonuses paid.
    For 2025 and 2024, pre-tax and Roth contributions are subject to annual Internal Revenue Code (Code) limitations of $23,500 and $23,000, respectively, plus a catch-up contribution of $7,500 for participants age 50 and older in both 2025 and 2024, with the exception of a higher catch-up contribution for participants ages 60 to 63 during plan year 2025. In 2025, the higher catch-up contribution amount is $11,250. Individual employee contributions of up to 6% of eligible compensation are eligible for a matching Company contribution. The Board of Directors of the Company may, within prescribed limits, establish, from time to time, the rate of Company contributions. The Plan authorizes the Company to make bi-weekly contributions to the Plan in an amount equal to 75% of eligible employee contributions during said period less any forfeitures. Employees can make pre-tax contributions, after-tax contributions, or Roth contributions. Employee contributions in pre-tax dollars result in savings going into the Plan before most federal, state or local taxes are withheld. Taxes are deferred until the employee withdraws the 401(k) contributions from the Plan.
    Prior to October 1, 2024, the Plan allowed for an additional non-elective contribution for employees hired or rehired on or after January 1, 2018 by BD and employees hired by C. R. Bard, Inc. (a subsidiary of Becton, Dickinson and Company) on or after January 1, 2011, or rehired on or after January 1, 2012. Beginning October 1, 2024, all employees were eligible for the additional non-elective contribution. The non-elective contribution under the Plan consists of a lump sum payment made to participants’ accounts following the end of each plan year and is calculated as a percentage of eligible compensation earned in the plan year, subject to annual limitations under the Code.
    The Plan Sponsor announced that effective January 1, 2027, that the non-elective contribution will be discontinued and the Company will make bi-weekly contributions to the Plan in an amount equal to 100% of eligible employee contributions during said period less any forfeitures.

    Participating employees are not liable for federal income taxes on amounts earned in the Plan or on amounts contributed by the Company until such time that their participating interest is distributed to them. In general, a participating employee is subject to tax on the amount by which the distribution paid to the employee exceeds the amount of after-tax dollars the employee has contributed to the Plan.
    Participant Accounts
    Each participant’s account is credited with the participant’s contribution and allocations of (a) the Company’s contribution and (b) Plan earnings, and charged with an allocation of administrative expenses,
    7



    when applicable. Allocations are based on participant earnings or account balances, as defined in the Plan document. The benefit to which a participant is entitled is the benefit that can be provided from the participant’s vested account.
    Investment Options
    A participant may direct his or her contributions to the following investment options, in increments of at least 1%, within the Plan:
    •Stable Value Investment Option, Synthetic GICs (see note 5),
    •Life Paycheck Index Retirement Funds Option,
    •U.S. Large Cap Stock Investment Option,
    •U.S. Mid Cap Stock Investment Option,
    •Non-U.S. Markets Stock Investment Option,
    •U.S. Small Mid Cap Stock Investment Option,
    •U.S. Capital Appreciation Investment Option,
    •Mutual Fund Investment Option, and
    •Company Common Stock Fund Investment Option.
    Any portion of the Plan’s assets, pending permanent investment or distribution, may be held on a short-term basis in cash or cash equivalents. The Vanguard Federal Money-Market account is a holding account and represents funds received awaiting allocation to an investment fund.
    Loan Provisions
    The Plan also has loan provisions whereby employees are allowed to take loans on their vested account balances. Loans originating during a year bear a fixed rate of interest which is set quarterly. Total loans to a participant cannot exceed the lesser of 50% of the participant’s vested balance or $50,000. Loans for any general purpose can have a term of up to 5 years. Loans for the purchase of a home can be up to 20 years. Employees are required to make installment payments at each payroll date. In case of termination, if the participant’s account balance is less than $1,000 the outstanding balance of a loan becomes due and payable upon the termination. If the participant elects not to repay the outstanding balance, the loan is canceled and deemed a distribution under the Plan. If the participant’s account balance is $1,000 or greater at the time of termination, the participant may elect to repay the outstanding loan balance or to continue to make monthly loan repayments on any outstanding loan balance. If the participant elects not to make monthly loan repayments and elects not to repay the outstanding balance, the loan is canceled and deemed a distribution under the Plan.
    Vesting
    The Plan provides for vesting in employer contributions (matching and non-elective contributions) based on years of service as follows:
    8



    Full Years of ServicePercentage
    Less than 2 years
    —%
    2 years but less than 3 years
    50
    3 years but less than 4 years
    75
    4 years or more
    100
    Participants become fully vested on the date of termination of employment by reasons of death, retirement or disability, or attainment of age 65. Participants may be partially vested under certain conditions in the event of termination of employment or participation in the Plan for any other reason. Non-vested Company contributions forfeited by participants are applied to reduce future Company contributions. Participants’ contributions are always 100% vested. Unallocated forfeitures balances as of December 31, 2025 and December 31, 2024, were $6,684,858 and $1,283,020, respectively. For the year ended December 31, 2025, forfeitures used to reduce Company matching contributions were $3,501,256.
    Payment of Benefits
    Upon separation from service with the Company due to retirement, a participant whose vested account balance exceeds $1,000 may elect to receive either a lump-sum payment or may elect to receive the balance in their account over a period of 2 to 15 years in monthly, quarterly, or annual installments. They may also elect to leave their balance in the Plan until April 1 of the calendar year following the year in which they turn 73 years of age.
    Upon separation from service with the Company due to termination, a participant whose vested account balance exceeds $1,000 may elect to receive a lump-sum payment. They may also elect to leave their balance in the Plan until April 1 of the calendar year following the year in which they turn 73 years of age.
    If upon termination or retirement, a participant’s vested account balance is $1,000 or less, they will automatically receive a cash lump-sum distribution equal to their vested account balance as soon as administratively possible after the participant’s termination or retirement.
    If the participant dies, the participant’s beneficiary will receive a lump sum distribution of their balance. If the beneficiary is the participant’s spouse, he/she may elect to defer payment to a later date.
    If the participant becomes disabled and qualifies for Social Security benefits, they may elect to receive a lump sum distribution of their account; otherwise, the account will remain active until the earlier of the date they turn age 65 or their death.
    In-service withdrawals are available in certain limited circumstances, as defined by the Plan. Hardship withdrawals are allowed for participants incurring an immediate and heavy financial need, as defined by the Plan. Hardship withdrawals are strictly regulated by the Internal Revenue Service (IRS) and require a participant to exhaust all available loan options and available distributions prior to requesting a hardship withdrawal.
    9



    Upon attainment of age 55, up to and including December 31 of the calendar year in which the participant attains age 71, participants can make non-hardship withdrawals (up to one third of the vested balance in the BlackRock LifePath Paycheck (LPP) funds) to directly purchase an annuity contract (with approved insurers) whereby payments from the annuity contract will begin after one month of its purchase.
    Plan Termination
    Although it has not expressed any intention to do so, the Board of Directors of the Company reserves the right to terminate, modify, alter or amend the Plan at any time and at its own discretion, subject to ERISA, provided that no such termination, modification, alteration or amendment shall permit any of the funds established pursuant to the Plan to be used for any purpose other than the exclusive benefit of the participating employees. The right to modify, alter or amend includes the right to change the percentage of the Company’s contributions. In the event of Plan termination, participants will become 100% vested in their accounts.
    3. Master Trust Information
    The Trustee holds all of the investments and is authorized to execute transactions. Financial information relating to the assets held by the Master Trust is included in the accompanying financial statements based on information provided by the Trustee. The Plan holds a divided interest in the assets of the Master Trust. The Plan’s share of net assets in the Master Trust and net appreciation, interest and dividends in the Master Trust, was determined by the Trustee as of December 31, 2025 and 2024 and for the year ended December 31, 2025 on the basis of the Plan’s specific ownership interest in the Master Trust’s underlying assets, plus the Plan’s cumulative contributions, less the Plan’s cumulative benefit payments and share of administrative expenses.
    Investment gains and administrative expenses related to the Master Trust are allocated to the individual plans based upon average monthly balances by each plan.
    The following tables present the Master Trust balances and the Plan’s interest in the Master Trust balances as of December 31, 2025 and 2024:

    Master Trust Balances as of December 31, 2025Plan’s interest in Master Trust Balances as of December 31, 2025
    Company common stock
    $228,264,940 

    $221,300,718 
    Common collective trusts
    5,547,791,181 

    5,460,537,926 
    Mutual funds
    234,860,058 

    232,970,000 
    Cash equivalents
    21,041,877 

    20,700,731 
    Total investments at fair value
    $6,031,958,056 

    $5,935,509,375 
    Investment contracts at contract value (see note 5)
    386,072,611 

    381,115,519 
    Total investments
    $6,418,030,667 

    $6,316,624,894 

    10




    Master Trust Balances as of December 31, 2024Plan’s interest in Master Trust Balances as of December 31, 2024
    Company common stock
    $309,098,578 

    $298,435,503 
    Common collective trusts
    4,863,355,623 

    4,794,935,812 
    Mutual funds
    201,558,912 

    200,155,977 
    Cash equivalents
    14,576,829 

    14,315,257 
    Total investments at fair value
    $5,388,589,942 

    $5,307,842,549 
    Investment contracts at contract value (see note 5)
    399,239,232 

    394,546,633 
    Total investments
    $5,787,829,174 

    $5,702,389,182 
    The following table presents the net appreciation in fair values of investment and investment income of the Master Trust and Plan for the Year Ended December 31, 2025:

    Master Trust BalancesPlan’s interest in Master Trust Balances
       Net appreciation
    $826,950,750 

    $815,326,799 
       Interest, dividends and other income
    30,659,229 

    30,215,532 
       Total investment income
    $857,609,979 

    $845,542,331 
    4. Fair Value Measurements
    Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (i.e., an exit price). The fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:
    Level 1 – Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Plan has the ability to access.
    Level 2 – Inputs to the valuation methodology include:
    •Quoted prices for similar assets or liabilities in inactive markets;
    •Inputs other than quoted prices that are observable for the asset or liability; and
    •Inputs that are derived principally from or corroborated by observable market data by correlation or other means.
    If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability.
    Level 3 – Inputs to the valuation methodology are unobservable and significant to the fair value measurement.
    11



    The asset’s or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques need to maximize the use of observable inputs and minimize the use of unobservable inputs.
    Following is a description of the valuation methodologies used for assets measured at fair value as of December 31, 2025 and December 31, 2024:
    Common collective trusts: Valued at the net asset value of shares held by the Plan at year end. These investments are determined to have a readily determinable fair value as the net asset value per unit is determined and published daily and is the basis for current transactions. These assets carry no restrictions on redemption.
    Cash equivalents: Comprised of investments in an institutional money market fund that permits daily redemption, the fair value of which is based upon the quoted price in active markets.
    Mutual funds: Valued at the net asset value of shares held by the Plan at year end, which are actively traded on an open market.
    Company common stock: Valued at the closing price reported on the active market in which the security is traded.
    The Plan's Investment Committee is responsible for determining the valuation policies and analyzing information provided by the investment custodians and issuers that is used to determine the fair value of the Master Trust’s investments. In determining the reasonableness of the methodology used, the Investment Committee evaluates a variety of factors, including review of existing contracts, economic conditions, industry and market developments and overall credit ratings.
    The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.
    The following tables set forth by level, within the fair value hierarchy, the Master Trust’s assets at fair value as of December 31, 2025 and December 31, 2024:

    Assets at Fair Value as of December 31, 2025

    Level 1
    Level 2Level 3Total
    Common collective trusts
    $5,547,791,181 — — $5,547,791,181 
    Cash equivalents
    21,041,877 — — 21,041,877 
    Mutual funds
    234,860,058 — — 234,860,058 
    Company common stock
    228,264,940 — — 228,264,940 
    Total investments at fair value
    $6,031,958,056 — — $6,031,958,056 
    12




    Assets at Fair Value as of December 31, 2024

    Level 1
    Level 2Level 3Total
    Common collective trusts
    $4,863,355,623 — — $4,863,355,623 
    Cash equivalents
    14,576,829 — — 14,576,829 
    Mutual funds
    201,558,912 — — 201,558,912 
    Company common stock
    309,098,578 — — 309,098,578 
    Total investments at fair value
    $5,388,589,942 — — $5,388,589,942 
    5. Fully Benefit-Responsive Investment Contracts
    Investment contracts represent Synthetic GICs. A Synthetic GIC consists of units of various collective trust funds that hold high quality fixed income securities, accompanied by one or more insurance company wrap contracts under which the issuer agrees to purchase fund assets at book value if a sale is needed in order to make benefit payments.
    In determining the net assets available for benefits, the Synthetic GICs are recorded at net contract value. Because the Synthetic GICs are fully benefit-responsive, contract value is the relevant measurement attribute for that portion of the net assets available for benefits attributable to the Synthetic GICs. Participants may ordinarily direct the withdrawal or transfer of all or a portion of their investment at contract value. There are currently no reserves against contract values for credit risk of the contract issuers or otherwise. Certain events limit the ability of the Master Trust to transact at contract value with the issuer. Such events include the following: (i) amendments to the plan documents (including complete or partial plan termination or merger with another plan); (ii) changes to plan’s prohibition on competing investment options or deletion of equity wash provisions; (iii) bankruptcy of the plan sponsor or other plan sponsor events (e.g., divestitures or spin-offs of a subsidiary) which cause a significant withdrawal from the Master Trust or the Plan or (iv) the failure of the Master Trust to qualify for exemption from federal income taxes or any required prohibited transaction exemption under ERISA. The Plan administrator does not believe that the occurrence of any such event, which would limit the Plan’s ability to transact at contract value with participants, is probable.
    Certain events could allow the issuers of the Synthetic GICs to terminate fully benefit-responsive investment contracts with the Plan and settle for an amount different from contract value. Examples of such events would include (i) the Plan’s loss of tax-exempt status, (ii) a material breach of responsibility by the Plan which cannot be corrected, or (iii) adverse changes to provisions of the Plan. The Plan administrator does not believe that the occurrence of any such event, which would cause termination of a contract for an amount different from contract value is probable.
    The Synthetic GICs do not permit the insurance companies to terminate the agreement prior to the scheduled maturity date. Each contract is subject to early termination penalties that may be significant.
    6. Income Tax Status
    The Plan has received a determination letter from the IRS dated March 7, 2023, stating that the Plan is qualified under Section 401(a) of the Code and, therefore, the related trust is exempt from taxation. Subsequent to receiving the determination letter, the Plan was amended. Once qualified, the Plan is
    13



    required to operate in conformity with the Code to maintain its qualification. The Plan administrator believes the Plan is being operated in compliance with the applicable requirements of the Code and therefore believes that the Plan, as amended and restated, is qualified and the related trust is tax-exempt.
    U.S. generally accepted accounting principles require plan management to evaluate uncertain tax positions taken by the Plan. The financial statement effects of a tax position are recognized when the position is more likely than not, based on the technical merits, to be sustained upon examination by the IRS. The Plan administrator has analyzed the tax positions taken by the Plan and has concluded that, there are no uncertain positions taken or expected to be taken. The Plan has recognized no interest or penalties related to uncertain tax positions. The Plan is subject to routine audits by taxing jurisdictions; however, there are currently no audits for any tax periods in progress.
    7. Related Parties and Party-In-Interest Transactions
    As of December 31, 2025, the Plan held 1,140,314 shares of the Company’s common stock with a fair value of $221,300,718. As of December 31, 2024, the Plan held 1,315,447 shares of the Company’s common stock with a fair value of $298,435,503. During the year, the Plan purchased and sold 28,018 shares for $5,425,048 and 203,151 shares for $39,682,481, respectively, of the Company’s common stock and received $5,095,305 in dividends on the shares of common stock.
    Party-in-interest transactions also include the Master Trust’s investments in certain common collective trusts and mutual funds that are managed by the investment managers of the Plan. Among which, Northern Trust funds held by the Master Trust are managed by Northern Trust, whereas Black Rock funds are managed by Black Rock, Inc., Fidelity funds are managed by the Trustee, Vanguard funds are managed by The Vanguard Group, and State Street funds are managed by State Street Global Advisors. These transactions qualify as party-in-interest transactions; however, they are exempt from the prohibited transaction rules under ERISA.
    8. Risks and Uncertainties
    The Master Trust and the Plan invests in various investment securities. Investment securities are exposed to various risks such as interest rate, market and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect participants’ account balances and the amounts reported in the statements of net assets available for benefits.

    9. Subsequent Events

    On February 9, 2026, the Company completed the spin-off to BD shareholders of the Company’s former Biosciences and Diagnostic Solutions business and the combination of the business with Waters Corporation (“Waters”) in a Reverse Morris Trust transaction (the “Transaction”). Consistent with other BD shareholders, the Master Trust received 0.135 shares of Waters for every share of Parent Company stock owned as of February 5, 2026, the record date for the Transaction. In connection with the Transaction, certain Company employees were transferred to Waters and these employees became fully
    14



    vested in Company contributions. No plan assets were transferred in connection with the Transaction, as transferred employees became eligible to participate in a Waters-sponsored defined contribution plan.
    15


















    SUPPLEMENTAL SCHEDULE

    16



    BD 401(k) Plan
    EIN #22-0760120 Plan #011
    Schedule of Assets 4(i)-(Held at End of Year)
    December 31, 2025

    Identity of Issue, borrower, lessor or similar party


    Description of investment, including maturity date, rate of interest, collateral, par or maturity value
    Current Value
    Notes receivable from participants*
    Interest rates ranging from 3.25% to 9.50%; maturities ranging from 2026-2047
    $72,906,552 
    * Represents a party-in-interest to the plan
    17



    BD 401(k) Plan
    SIGNATURES


    Pursuant to the requirements of the Securities and Exchange Act of 1934, the Plan Administrative Committee of Becton, Dickinson and Company the Plan Administrator of the BD 401(k) Plan, has duly caused the annual report to be signed on its behalf by the undersigned hereunto duly authorized.
    BD 401(k) Plan
    Dated: June 29, 2026/s/ Kristi Payne
    Kristi Payne, Member, Plan Administrative Committee
    18



    Exhibits
    Exhibit No.Document
    23
    Consent of Independent Registered Public Accounting Firm
    19

    Get the next $BDX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BDX

    DatePrice TargetRatingAnalyst
    5/4/2026$180.00Outperform
    Evercore ISI
    4/10/2026$167.00Neutral
    Goldman
    2/10/2026$202.00Overweight
    Barclays
    2/3/2026$233.00Buy
    Citigroup
    9/25/2025$211.00Sector Perform
    RBC Capital Mkts
    5/22/2025$185.00Buy → Neutral
    Citigroup
    5/2/2025$185.00Overweight → Neutral
    Piper Sandler
    5/2/2025$192.00Buy → Neutral
    Goldman
    More analyst ratings

    $BDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI resumed coverage on Becton Dickinson with a new price target

    Evercore ISI resumed coverage of Becton Dickinson with a rating of Outperform and set a new price target of $180.00

    5/4/26 8:48:11 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Goldman resumed coverage on Becton Dickinson with a new price target

    Goldman resumed coverage of Becton Dickinson with a rating of Neutral and set a new price target of $167.00

    4/10/26 12:23:31 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Barclays resumed coverage on Becton Dickinson with a new price target

    Barclays resumed coverage of Becton Dickinson with a rating of Overweight and set a new price target of $202.00

    2/10/26 7:21:54 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 23, 2021 - Coronavirus (COVID-19) Update: November 23, 2021

    For Immediate Release: November 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On Nov. 22, the FDA authorized three over-the-counter (OTC) COVID-19 antigen diagnostic tests for people age 14 years or older with a self-collected nasal swab sample or people age 2 years or older when an adult collects the nasal swa

    11/23/21 3:16:12 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    July 23, 2021 - Coronavirus (COVID-19) Update: July 23, 2021

    For Immediate Release: July 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: The agency updated its FDA COVID-19 Response At-A-Glance Summary, which provides a quick look at facts, figures and highlights on the FDA's response efforts. On Thursday, July 22 the FDA issued an Emergency Use Authorization (EUA) to Bec

    7/23/21 4:06:11 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & President Connected Care Muhsin Bilal was granted 14,342 shares and covered exercise/tax liability with 1,935 shares, increasing direct ownership by 43% to 41,359 units (SEC Form 4) (for withholding tax)

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    7/6/26 3:16:13 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    EVP, Chief Revenue Officer Feld Michael sold $11,460 worth of shares (75 units at $152.80) as part of a pre-agreed trading plan, decreasing direct ownership by 0.36% to 21,009 units (SEC Form 4)

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    6/26/26 8:47:39 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    EVP & Pres Med.Essntl&BioPharm Garrison Michael David sold $160,226 worth of shares (1,100 units at $145.66) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 13,172 units (SEC Form 4)

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    6/25/26 10:16:01 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BD to Announce Financial Results for its Third Quarter of Fiscal 2026

    FRANKLIN LAKES, N.J., July 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m. ET on Thursday, August 6, 2026 to discuss the Company's financial results for its third quarter of fiscal year 2026, which ended on June 30, 2026, and to provide an update on its operations and strategy. The audio webcast can be accessed at BD's investor relations website at www.bd.com/investors, and a replay will be made available shortly after the call at the same website. Prior to the call, the Company will issue a news release and related presentation materials that will inclu

    7/9/26 4:15:00 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    BD Awarded Vizient Innovative Technology Contract for CentroVena One™ Insertion System

    Recognition from Vizient validates CentroVena One™ as a breakthrough innovation designed to simplify central line insertion and enhance patient and clinician safetyFRANKLIN LAKES, N.J., June 23, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that its BD® CentroVena One™ Insertion System has been awarded an Innovative Technology contract from Vizient®, the nation's largest provider-driven healthcare performance improvement company. This contract recognizes products with the potential to drive meaningful improvements in healthcare delivery. The cont

    6/23/26 6:50:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    BD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System

    New laser system is designed to help urology teams enhance efficiency, versatility, and procedural workflow across stone management and soft tissue procedures.FRANKLIN LAKES, N.J., May 21, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the introduction of the Elyra™ Thulium Fiber Laser (TFL) System, an advanced laser platform developed to complete BD's kidney stone care portfolio for urology teams. Designed to enhance efficiency, versatility, and procedural workflow across urologic stone management and soft tissue procedures, the innovative new system supports consistent performance in demanding clinical enviro

    5/21/26 6:50:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    SEC Filings

    View All

    $BDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 11-K filed by Becton Dickinson and Company

    11-K - BECTON DICKINSON & CO (0000010795) (Filer)

    6/29/26 4:20:23 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    SEC Form 11-K filed by Becton Dickinson and Company

    11-K - BECTON DICKINSON & CO (0000010795) (Filer)

    6/29/26 4:18:28 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Becton Dickinson and Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - BECTON DICKINSON & CO (0000010795) (Filer)

    5/29/26 8:39:28 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Director Hayes Gregory bought $1,005,742 worth of shares (5,250 units at $191.57), increasing direct ownership by 660% to 6,046 units (SEC Form 4)

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    8/11/25 4:15:55 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Director Henderson Jeffrey William bought $350,430 worth of shares (1,500 units at $233.62), increasing direct ownership by 23% to 8,015 units (SEC Form 4)

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    2/10/25 5:03:18 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Leadership Updates

    Live Leadership Updates

    View All

    BD Appoints Vitor Roque Chief Financial Officer

    FRANKLIN LAKES, N.J., May 7, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that Vitor Roque has been named executive vice president and chief financial officer (CFO), effective May 7. Roque has served as interim CFO since December 2025. With more than 25 years at BD, Roque has held senior finance and operations roles across the company, most recently as senior vice president, Finance and Corporate Financial Planning and Analysis. During his tenure as interim CFO, he led BD's global finance functio

    5/7/26 6:31:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Waters Completes Combination with BD's Biosciences & Diagnostic Solutions Businesses

    Announces appointment of Claire M. Fraser, Ph.D., to its Board of DirectorsForms a global life sciences and diagnostics leader focused on high-volume testing in regulated applicationsAnnounces formation of four divisions: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials SciencesMILFORD, Mass., Feb. 9, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) ("Waters") today announced it has completed the previously announced combination with the Biosciences & Diagnostic Solutions businesses of Becton, Dickinson and Company (NYSE:BDX) ("BD"). The transaction forms a global life sciences and diagnostics leader, equipped with best-in-class technologies

    2/9/26 8:40:00 AM ET
    $BDX
    $WAT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    BD Appoints Robert Huffines and Jacqueline Wright to Board of Directors

    FRANKLIN LAKES, N.J., Nov. 17, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the appointment of Robert "Robbie" Huffines and Jacqueline "Jacky" Wright to its board of directors, effective Dec. 1, 2025. "Robbie and Jacky will further strengthen the BD board with deep expertise in health care, technology, digital transformation and artificial intelligence, as well as finance and capital markets, all of which are core to the continued advancement of our strategy," said Tom Polen, chairman, CEO and

    11/17/25 4:30:00 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Becton Dickinson and Company (Amendment)

    SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)

    2/16/24 4:29:42 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Becton Dickinson and Company (Amendment)

    SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)

    2/14/24 10:02:59 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Becton Dickinson and Company (Amendment)

    SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)

    2/13/24 5:00:53 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Financials

    Live finance-specific insights

    View All

    BD Reports Second Quarter Fiscal 2026 Financial Results

    Revenue of $4.7 billion increased 5.2% as reported, 2.6% FXNGAAP and adjusted diluted EPS from continuing operations of $(0.13) and $2.90, respectivelyExecuted a $2.0 billion accelerated share repurchase (ASR) program and retired $2.1 billion of debt in the quarterCompany reaffirms revenue growth guidance, raises full-year adjusted diluted EPS guidance1FRANKLIN LAKES, N.J., May 7, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced results for its fiscal 2026 second quarter, which ended March 31, 2026. "We delivered a solid second quarter, with revenue, margins and EPS all ahead of our expectations," said Tom Polen,

    5/7/26 6:30:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    BD Board Declares Dividend

    FRANKLIN LAKES, N.J., April 28, 2026 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $1.05 per common share, payable on June 30, 2026, to holders of record on June 9, 2026. The indicated annual dividend rate is $4.20 per share. About BDBD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologi

    4/28/26 4:15:00 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    BD Reports First Quarter Fiscal 2026 Financial Results

    Revenue of $5.3 billion increased 1.6% as reported, 0.4% FXNNew BD revenue increased 2.5% FXNGAAP and adjusted diluted EPS of $1.34 and $2.91, respectivelyCombination of BD's Biosciences and Diagnostic Solutions business with Waters Corporation expected to close todayCompany affirms FY26 revenue growth guidance, provides Adjusted Diluted EPS guidance for New BDFRANKLIN LAKES, N.J., Feb. 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced results for its fiscal 2026 first quarter, which ended December 31, 2025. "We delivered stronger‑than‑expected first‑quarter performance which reflects our disciplined execution

    2/9/26 6:30:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care